Drug Channels

JANUARY 5, 2021

It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. I also review the factors behind declining brand-name drug prices.

Drug Pricing 52

Drug Pricing 52

STAT

OCTOBER 18, 2024

Some $38 billion in prescription medications were purchased under the 340B program in 2020, for instance, which was up from $16.2 Since it began more than 30 years ago, the program has ballooned and fed into the national clash over the cost of medicines. billion in 2016. Continue to STAT+ to read the full story…

Hospitals 332

Hospitals Drug Pricing 332

pharmaphorum

JULY 22, 2022

Two years later, the CAT found that while they had a dominant position in the market, there wasn’t sufficient evidence that the prices being charged were an abuse of that position. ” The post Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe appeared first on.

Drug Pricing 111

Drug Pricing 111

Drug Channels

MARCH 23, 2021

It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. I also review the factors behind declining brand-name drug prices.

Drug Pricing 52

Drug Pricing 52

STAT

NOVEMBER 28, 2023

Eliquis is one of 10 high-cost drugs the federal program has targeted first for negotiated prices. “The manufacturer of that drug spent most of 2020 in court trying to fend off generic competition,” she said at a Tuesday STAT event in Washington D.C. Continue to STAT+ to read the full story…

Drug Pricing 296

Drug Pricing 296

pharmaphorum

FEBRUARY 4, 2022

Our findings also indicated that disease rarity cannot be used to predict the likelihood of reimbursement and thus is not a major driver of reimbursement decisions in either NICE or NHS England value assessments for rare and orphan disease drugs. Link between disease rarity and drug pricing. appeared first on.

Drug Pricing 103

Drug Pricing Drug Development 103

STAT

NOVEMBER 28, 2022

A hotly contested provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare $1.5 billion from 2015 to 2020 — or nearly 5% of the $30.2 billion spent by the health care program — on just five medicines during that period, according to a new analysis.

Labelling 252

Labelling Biosimilars Drug Pricing 252

STAT

JANUARY 3, 2023

More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.

Immunity 246

Immunity Immunization Hospitals Drug Pricing 246

STAT

MAY 16, 2023

Horizon’s Tepezza, a treatment approved by the Food and Drug Administration in 2020 for moderate to severe thyroid eye disease, has yearly sales approaching $2 billion.   The acquisition, announced in December, was seen as another move by a large pharma company to build out its rare disease pipeline.

Drug Pricing 245

Drug Pricing 245

STAT

SEPTEMBER 23, 2022

billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025. According to the most recent “U.S. Generic & Biosimilar Medicines Savings Report” from the Association for Accessible Medicines, biosimilar savings in the U.S. Read the rest…

Biosimilars 245

Biosimilars Diabetes Drug Pricing 245

Drug Channels

SEPTEMBER 30, 2020

We’ve been squirrelling away these acorns from the mighty Drug Channels oaks: I agree. Brand-name drugs prices keep on dropping It’s official: CVS Health’s Zinc GPO actually exists! Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Autumn is here! You can also join my 23.3K

Drug Pricing 52

Drug Pricing 52

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. Click here to see the original post and comments from October 2020. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Biosimilars 52

Biosimilars Drug Pricing 52

STAT

AUGUST 7, 2023

At issue is a partnership that began in 2017 to develop and potentially market a drug, known as Rezpeg, to treat various autoimmune diseases, and in particular, eczema. billion in 2020 to acquire another company called Dermira, which was developing a competing medication to treat atopic dermatitis, according to the lawsuit.

Drug Development 236

Drug Development Drug Pricing 236

Drug Channels

OCTOBER 6, 2020

What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. Last year, Dr. Scott Gottlieb, a former FDA commissioner, argued that we shouldn’t give up on biosimilars and prematurely regulate prices. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Biosimilars 52

Biosimilars Drug Pricing 52

Drug Channels

DECEMBER 8, 2020

When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.

Drug Pricing 52

Drug Pricing 52

RX Note

APRIL 16, 2023

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Confidential price discounts prevents everyone from demanding the lowest available price.

Drug Pricing 40

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 40

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Drug Pricing 102

Drug Pricing Drug Development 102

Drug Channels

MARCH 25, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. Click here to see the original post and comments from December 2020. drug channel. d/b/a Drug Channels Institute. But I can dream, can’t I?

Drug Pricing 52

Drug Pricing 52

Drug Channels

OCTOBER 12, 2020

Informa Connect-CBI’s 6th Edition Drug Pricing Transparency Congress. November 16-17, 2020 | Virtual Event www.informaconnect.com/drug-pricing-transparency. Drug Channels Readers: View the complete agenda and register today. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Drug Pricing 40

Drug Pricing 40

Big Molecule Watch

APRIL 22, 2024

Department of Justice (“DOJ”) filed a lawsuit under the Anti-Kickback Statute against Regeneron Pharmaceuticals in the District of Massachusetts regarding Regeneron’s sales of Eylea in 2020. The post DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing appeared first on Big Molecule Watch.

Drug Pricing 49

Drug Pricing 49

Drug Channels

JUNE 24, 2020

My recent tweets have highlighted: Amazon’s activities, PillPack’s bad reviews, 340B outrages, rebate reform redux, biosimilar pricing, managed Medicaid market shares, drug pricing, blockchain hype, and the warp speed vs. hyperspace debate. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Drug Pricing 52

Drug Pricing Biosimilars 52

Drug Channels

SEPTEMBER 22, 2021

Despite what you may have heard, the 340B Drug Pricing Program continues to thrive. Discounted purchases under the program reached at least $38 billion in 2020. Drug Channels has exclusively obtained the 2020 amount from the Health Resources and Services Administration (HRSA).

Drug Pricing 45

Drug Pricing Hospitals 45

Drug Channels

AUGUST 15, 2022

Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! billion (+15.6%) higher than its 2020 counterpart. billion (+15.6%) higher than its 2020 counterpart. The data tell a familiar story.

Hospitals 98

Hospitals Drug Pricing 98

Drug Channels

MARCH 8, 2022

Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. Pharmacies and Pharmacy Benefit Managers. prescription dispensing revenues for calendar year 2021.

Drug Pricing 98

Drug Pricing 98

Drug Channels

JUNE 8, 2021

The Bureau of Labor Statistics (BLS) has recently released its employment and salary data for 2020. That means it’s time to update Drug Channels Institute’s (DCI) annual analysis of pharmacist salaries and employment. I suspect that 2020 will turn out to have been a much more challenging year for retail-employed pharmacists.

Hospitals 40

Hospitals Physician Offices Drug Pricing 40

Drug Channels

JUNE 16, 2021

Despite what you may have heard, the 340B Drug Pricing Program continues to thrive. Discounted purchases under the program reached at least $38 billion in 2020. Drug Channels has exclusively obtained the 2020 amount from the Health Resources and Services Administration (HRSA).

Drug Pricing 40

Drug Pricing Hospitals 40

Drug Channels

JUNE 24, 2021

It’s the 12th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. You can preorder at special discounted prices.). prescription dispensing revenues for calendar year 2020. prescription dispensing revenues reached a record $465 billion in 2020.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

pharmaphorum

MARCH 10, 2022

billion settlement in 2020 which was finally accepted last month. The US government filed a complaint in the same year claiming Mallinckrodt unlawfully required Medicaid programmes to foot the bill for an increase in the price of Acthar Gel from $50 per vial to $28,000 per vial, according to the Department of Justice.

Drug Pricing 105

Drug Pricing Pharmaceutical Manufacturing 105

Drug Channels

MARCH 9, 2021

It’s the 12th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. You can preorder at special discounted prices.). prescription dispensing revenues for calendar year 2020. prescription dispensing revenues reached a record $465 billion in 2020.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

Proxsys Rx

MAY 1, 2023

Court of Appeals for the Third Circuit — which was largely in favor of three drug companies that have imposed harmful limits on safety-net hospitals’ access to 340B drug pricing program discounts. For more information, contact Howard Hall.

Drug Pricing 52

Drug Pricing Hospitals Specialty Pharmacies 52

Proxsys Rx

APRIL 10, 2023

Court of Appeals for the Third Circuit — which was largely in favor of three drug companies that have imposed harmful limits on safety-net hospitals’ access to 340B drug pricing program discounts. For more information, contact Howard Hall.

Drug Pricing 52

Drug Pricing Hospitals Specialty Pharmacies 52

Drug Channels

DECEMBER 16, 2022

Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! billion (+15.6%) higher than its 2020 counterpart. Click here to see the original post and comments from August 2022. billion (+$7.0

Hospitals 97

Hospitals Drug Pricing 97

Pharmaceutical Technology

SEPTEMBER 15, 2022

The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

Drug Channels

AUGUST 11, 2020

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, drug prices declined—or grew slowly—in 2019. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Drug Pricing 52

Drug Pricing Pharmaceutical Manufacturing 52

pharmaphorum

JANUARY 28, 2021

In 2020, we saw seven of the 20 biosimilars currently available in the US launch. The United States biosimilar market experienced a significant increase in competition in 2020. As a result of the regulatory changes that occurred in March 2020, the first potential insulin biosimilar is on the horizon. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

Putting Patients First Blog

NOVEMBER 14, 2023

NHC Comments on Request for Information: Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program (PDF) November 13, 2023 Benjamin Stidham, Contract Specialist Centers for Medicare & Medicaid Services U.S. Barriers to ensuring access to affordable prescription drugs. Sincerely, Randall L.

Drug Pricing 40

Drug Pricing Specialty Pharmacies HIPAA Payment Processing 40

Pharmaceutical Technology

NOVEMBER 21, 2022

According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69